Restart Trial





Follow-up ongoing

Participants are under active follow-up until 30 November 2020. The follow-ups will continue to be requested from GPs and participants, or their carers. The new trial end date is 28 February 2021.

Recruitment closed

Recruitment closed at 12pm on 31 May 2018. We have recruited 537 patients. We will complete follow-up at the end of 2018 and plan to present the results of the trial at the 5th European Stroke Organisation Conference in Milan, 22-24 May 2019.

What is RESTART?

RESTART is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e. anticoagulant or antiplatelet medication) for the prevention of vaso-occlusive disease before the ICH.

RESTART is testing whether a policy of starting antiplatelet drugs (one or more of aspirin, clopidogrel, or dipyridamole, chosen at investigator's discretion) results in a beneficial net reduction of all serious vascular events over two years compared with a policy of avoiding antiplatelet drugs.

RESTART began recruitment in the United Kingdom in May 2013.

Who is running RESTART?

RESTART is run by a team from the University of Edinburgh, in collaboration with researchers at the University of Dundee, the University of Newcastle-upon-Tyne, and University College London.

RESTART is overseen by a Steering Committee led by an independent chairperson, with representation from the British Heart Foundation.

RESTART accumulating data is overseen by a completely independent Data Monitoring Committee.